FY2025 EPS Estimates for Repligen Boosted by William Blair

Key Points

• William Blair has raised its FY2025 earnings estimate for Repligen to $1.69 per share, slightly up from the previous estimate of $1.68, although the consensus estimate remains at $1.72.
• Several analysts, including Stephens and Royal Bank Of Canada, have given Repligen a positive outlook with upgrade ratings and price targets ranging from $150.00 to $204.00.
• Despite a quarterly earnings miss, Repligen's revenue increased by 14.8% year-over-year, reporting $182.37 million compared to estimates of $174.62 million.

Repligen Corporation (NASDAQ:RGEN - Free Report) - Research analysts at William Blair lifted their FY2025 earnings per share (EPS) estimates for shares of Repligen in a research report issued to clients and investors on Tuesday, July 29th. William Blair analyst M. Larew now anticipates that the biotechnology company will post earnings per share of $1.69 for the year, up from their prior estimate of $1.68. The consensus estimate for Repligen's current full-year earnings is $1.72 per share. William Blair also issued estimates for Repligen's Q1 2026 earnings at $0.53 EPS, Q3 2026 earnings at $0.57 EPS and Q4 2026 earnings at $0.69 EPS.

Repligen (NASDAQ:RGEN - Get Free Report) last issued its quarterly earnings results on Tuesday, July 29th. The biotechnology company reported $0.37 earnings per share for the quarter, missing analysts' consensus estimates of $0.40 by ($0.03). The company had revenue of $182.37 million during the quarter, compared to analysts' expectations of $174.62 million. Repligen had a positive return on equity of 4.65% and a negative net margin of 2.05%. The company's revenue for the quarter was up 14.8% compared to the same quarter last year. During the same period in the prior year, the business posted $0.40 EPS.

Other equities research analysts have also issued reports about the company. Royal Bank Of Canada raised their price objective on Repligen from $193.00 to $204.00 and gave the stock an "outperform" rating in a research report on Wednesday. Evercore ISI decreased their price objective on Repligen from $140.00 to $130.00 and set an "in-line" rating for the company in a research report on Tuesday, July 8th. Barclays began coverage on Repligen in a research report on Tuesday, June 24th. They set an "overweight" rating and a $150.00 price objective for the company. Wolfe Research upgraded Repligen from a "peer perform" rating to an "outperform" rating and set a $160.00 price objective for the company in a research report on Tuesday, April 29th. Finally, Canaccord Genuity Group decreased their price objective on Repligen from $170.00 to $150.00 and set a "hold" rating for the company in a research report on Wednesday, April 16th. Five investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $169.45.

Repligen Trading Up 1.6%

RGEN traded up $1.84 during trading on Thursday, reaching $118.91. The company had a trading volume of 941,488 shares, compared to its average volume of 948,438. The firm's 50-day simple moving average is $123.39 and its 200 day simple moving average is $136.49. The company has a market cap of $6.68 billion, a price-to-earnings ratio of -475.62, a PEG ratio of 2.15 and a beta of 1.05. Repligen has a 12-month low of $102.96 and a 12-month high of $182.52. The company has a debt-to-equity ratio of 0.27, a quick ratio of 5.79 and a current ratio of 6.79.

Institutional Investors Weigh In On Repligen

Institutional investors have recently made changes to their positions in the company. Price T Rowe Associates Inc. MD lifted its holdings in Repligen by 6.0% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 7,566,093 shares of the biotechnology company's stock worth $962,711,000 after purchasing an additional 430,039 shares during the last quarter. Champlain Investment Partners LLC lifted its holdings in Repligen by 8.6% in the 4th quarter. Champlain Investment Partners LLC now owns 1,543,530 shares of the biotechnology company's stock worth $222,176,000 after purchasing an additional 122,595 shares during the last quarter. Alliancebernstein L.P. lifted its holdings in Repligen by 1.3% in the 1st quarter. Alliancebernstein L.P. now owns 1,024,180 shares of the biotechnology company's stock worth $130,317,000 after purchasing an additional 13,284 shares during the last quarter. Conestoga Capital Advisors LLC lifted its holdings in Repligen by 3.4% in the 1st quarter. Conestoga Capital Advisors LLC now owns 980,247 shares of the biotechnology company's stock worth $124,727,000 after purchasing an additional 32,665 shares during the last quarter. Finally, Point72 Asset Management L.P. lifted its holdings in Repligen by 183.1% in the 4th quarter. Point72 Asset Management L.P. now owns 918,623 shares of the biotechnology company's stock worth $132,227,000 after purchasing an additional 594,189 shares during the last quarter. 97.64% of the stock is currently owned by institutional investors and hedge funds.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.